Replacement of the Airways and/or the Pulmonary Vessels Using a Cryopreserved Arterial Allograft
Surgery remains the best option for curative treatment of early stages Non-Small Cell Lung
Cancer (NSCLC). Peripheral tumors are usually resected using lobectomy with a low 90-day
morbidity and mortality rate (2%). Central NSCLC often require a pneumonectomy with a high
90-day morbidity and mortality rate (up to 24%), especially when some factors are present:
age > 70 years, right side, neoadjuvant chemoradiotherapy. On the other hand, bronchoplastic
lobectomies have been proposed in order to avoid pneumonectomy. However, more than fifty
years after their first description, bronchoplastic lobectomies remain uncommon (<1% of all
pulmonary resection). This could be explained by some technical difficulties showing the
potential interest of a bronchial substitute. In a 10-year research phase on a sheep model
(n=108), we demonstrated that aortic grafts could be valuable substitutes for
tracheobronchial replacement. We observed a progressive transformation of the aortic tissue
into airway tissue comprising epithelium and regenerated cartilage. The technique was
extended to clinical tracheal replacement by us and others with encouraging results. We
proposed to evaluate the feasibility of the use of a stent-supported cryopreserved aortic
allograft as a bronchial substitute to prevent pneumonectomy and its associated high
mortality rate in NSCLC surgery. Primary outcome will be the 90-day mortality. Secondary
outcomes will be the postoperative complications, the 90-day morbidity. This prospective
open study will include 20 to 30 patients according to eligibility criteria (see below). The
operation will consist of the curative resection of the NSCLC followed by the replacement of
a bronchial segment using a cryopreserved allograft in order to re-implant a functional
pulmonary lobe. A stent will be placed in the graft to prevent airway collapse.
-Current study (TRACHEO BRONC-ART) The BRONC-ART study was extended to major (malignant or
benign) lesions of the trachea requiring airway transplantation. For these patients,
resection followed by direct end to end anastomosis is not possible or at high risk.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
90-day mortality
3 months
Yes
Emmanuel MARTINOD, Pr, PhD
Study Director
Assistance Publique - Hôpitaux de Paris
France: Ministry of Health
P091203
NCT01331863
May 2011
December 2013
Name | Location |
---|